SolaranRx, Inc., which is developing a peptide-based technology for treating metastatic melanoma, is among the featured presenters at the Third Annual Sachs Cancer Bio Partnering & Investment Forum on February 23 at the New York Academy of Sciences in New York City. SolaranRx’s lead product, SRX-1177, was recently selected among the 2014 Top 10 Most Interesting Oncology Projects to Watch by Informa and Kantar Health for its strong science and potential to address unmet medical needs in treating metastatic melanoma.
Help employers find you! Check out all the jobs and post your resume.
